Key Takeaways
- • Citizens maintained its Market Outperform rating on Ares Management (NYSE: ARES) and kept its price target at $160.00, per Investing.com, published October 9, 2026.
- • The $160 target implies roughly 38% upside from the stock's $116.26 trading price cited in the report.
- • Citizens' target is based on approximately 22 times Ares' 2027 after-tax realized income per-share estimate, the highest valuation multiple in the firm's group.
- • Citizens cites broad fundraising and more than $800 million of potential management fees embedded in existing capital as support for the premium valuation.
- • Ares trades at 20.2 times its 2026 distributable earnings estimate and 15.9 times its 2027 estimate, with a reported trailing P/E of 53.47.
Summary
Citizens maintained its Market Outperform rating on Ares Management, L.P. (NYSE: ARES) and reiterated its $160.00 price target, according to Investing.com. At the time of the report, the shares traded at $116.26, well below the target. Citizens noted that Ares trades at 20.2 times its 2026 distributable earnings estimate and 15.9 times its 2027 estimate.
The firm's $160 target is derived from approximately 22 times Ares' 2027 after-tax realized income per-share estimate. Citizens described this multiple as the highest in its coverage group. The stock's reported trailing P/E ratio of 53.47 reflects a high earnings multiple, which the report attributes to the market's pricing of the company's growth profile.
Citizens argued that the premium valuation is supported by broad fundraising momentum and more than $800 million of potential management fees embedded in existing capital. The firm also said Ares' business mix can benefit from higher interest rates even before sponsor-related mergers, acquisitions and realizations fully recover. Publisher context notes that Ares reported record second-quarter fundraising of $36 billion and 20% fee-related earnings growth in July, and that Citizens' earlier commentary pointed to strong performance through cycles and rising capital inflows across the sector.
Other recent coverage includes Piper Sandler's initiation of coverage with an overweight rating and a $150 price target. Ares manages $671 billion in assets, a significant portion of which is in credit. The company is also leading a $2.2 billion direct loan supporting MedImpact Holdings Inc.'s acquisition of Medical Card System, Inc.
The firm's $160 target is derived from approximately 22 times Ares' 2027 after-tax realized income per-share estimate. Citizens described this multiple as the highest in its coverage group. The stock's reported trailing P/E ratio of 53.47 reflects a high earnings multiple, which the report attributes to the market's pricing of the company's growth profile.
Citizens argued that the premium valuation is supported by broad fundraising momentum and more than $800 million of potential management fees embedded in existing capital. The firm also said Ares' business mix can benefit from higher interest rates even before sponsor-related mergers, acquisitions and realizations fully recover. Publisher context notes that Ares reported record second-quarter fundraising of $36 billion and 20% fee-related earnings growth in July, and that Citizens' earlier commentary pointed to strong performance through cycles and rising capital inflows across the sector.
Other recent coverage includes Piper Sandler's initiation of coverage with an overweight rating and a $150 price target. Ares manages $671 billion in assets, a significant portion of which is in credit. The company is also leading a $2.2 billion direct loan supporting MedImpact Holdings Inc.'s acquisition of Medical Card System, Inc.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.